Health minister Dzulkefly says the government did not set aside dedicated 2026 budget funds for the two GLP-1 treatments.
Recap by typeshit. Post by The Malaysian Reserve on X.
Sales missed forecasts by about $33 million, but Lilly says demand more than tripled. Novo's Wegovy pill still holds roughly 75% of oral GLP-1 scripts.
Employers pick their own contribution toward semaglutide shots or pills. AJMC notes WTW found GLP-1 weight loss coverage fell to 53% of employers, the first drop in three years.
Volume rose 53% while prices dropped, a sign cheaper access is pulling in patients. Breakdown covers LillyDirect pricing, the $50 Medicare Bridge and Novo's 2027 cuts.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Loading…